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PROTEOLIPOSOMES DARIPADA Mycobacterium bovis BCG DAN 
Mycobacterium smegmatis SEBAGAI CALON-CALON VAKSIN YANG 
BAHARU TERHADAP TUBERCULOSIS 
 
ABSTRAK 
Tuberculosis (TB) adalah disebabkan oleh Mycobacterium tuberculosis (Mtb). 
Penyakit ini adalah jangkitan yang boleh membawa maut dan ia merupakan salah 
satu daripada punca utama kematian dan penyakit di dunia. Bakteria ini biasanya 
menyerang paru-paru dan anggota badan yang lain seperti otak, buah pinggang dan 
tulang belakang. Bacille Calmette-Gúerin (BCG) merupakan vaksin yang digunakan 
secara meluas di seluruh dunia dan ia merupakan satu-satunya vaksin yang 
digunakan untuk mencegah TB. Kajian menunjukkan BCG dapat melindungi atau 
sekurang-kurangnya mencegah TB sistemik yang teruk pada kanak-kanak, 
terutamanya meningitis TB. Walau bagaimanapun, BCG kurang atau tidak dapat 
memberi perlindungan terhadap penyakit TB pulmonari pada orang dewasa. Maka, 
calon vaksin yang lebih efektif berbanding BCG adalah sangat diperlukan untuk 
mencegah penyakit TB serta penularannya. Dengan mengambil kira persamaan 
genomik and antigenik di antara Mtb dan bakteria tidak patogenik seperti BCG dan 
Mycobacterium smegmatis (Ms), kami menghasilkan proteoliposomes (PLs) 
daripada BCG dan Ms sebagai calon vaksin terhadap penyakit TB. Kajian 
bioinformatik yang telah dilakukan dan keputusannya menunjukkan kewujudan 
epitope-epitop sel T dan B di dalam PLs daripada BCG dan Ms yang serupa dengan 
yang dihasilkan secara in vivo oleh Mtb semasa peringkat jangkitan. Keputusan 
penentuan antigen leukosit manusia (HLA) telah menunjukkan epitop-epitop ini  
 xvii 
 
memberikan peratusan yang terbaik dalam populasi Melayu dan Cuba. Oleh sebab 
itu, PLs daripada BCG (PLBCG) dan Ms (PLMs) telah dihasilkan untuk menilai 
keimunogenan dan  tindak  balas reaktif silang terhadap antigen-antigen daripada 
Mtb. PLs ini telah disahkan berbentuk sfera dan mempunyai sifat yang sama dari 
segi saiz dan bentuk di bawah pemerhatian mikroskop elektron dan kajian 
kromatografi. Pada peringkat seterusnya, kajian antigenisiti terhadap PLBCG and 
PLMs di dalam manusia telah dilakukan. Keputusan menunjukkan  individu-individu 
yang sihat telah menghasilkan IFN-γ, yang mungkin disebabkan oleh imunisasi BCG 
dan pendedahan kepada mikrobakteria persekitaran. Sebaliknya, pesakit TB 
menunjukkan tindak balas penghasilan IFN-γ yang rendah terhadap PLs, ini 
berkemungkinan disebabkan oleh kelemahan sistem imun dan faktor-faktor genetik. 
Tambahan pula, keputusan esei imunoserapan berkaitan enzim (ELISA) dan analisa 
pemblotan Western, menunjukkan sera daripada pesakit TB dapat bertindak balas 
dengan protein-protein yang terdapat di dalam PLs. Ini menunjukkan bahawa PLs 
mengandungi antigen-antigen yang diekspres secara in vivo ketika peringkat 
jangkitan TB yang aktif. Kajian haiwan pula menunjukkan bahawa mencit yang 
diimunisasi PLBCG yang digabungkan dengan adjuvan alum (AL) telah 
menghasilkan tindak balas imun humoral yang spesifik dengan mecetuskan tindak 
balas campuran Th1 dan Th2 serta tindak balas selular yang spesifik secara in vivo 
melalui tindak balas hipersensitiviti jenis lewat (DTH) yang positif terhadap PLBCG. 
Imunisasi mencit dengan kombinasi PLBCG dan Montanide ISA 51 VG (MT) telah 
mencetuskan jenis tindak balas Th2. Kumpulan mencit yang diimunisasi PLMs 
dengan kombinasi AL telah menghasilkan tindak balas antibodi yang spesifik dengan 
mencetuskan bentuk tindak balas Th2. Splenosit daripada mencit PLMs tanpa 
adjuvan telah menghasilkan tindak balas Th2 dalam penghasilan sitokin secara in 
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vitro. Kedua-dua kumpulan mencit PLBCG dan PLMs diadjuvankan dengan alum 
dan kombinasi PLBCG dengan adjuvan MT telah menghasilkan tindak  balas reaktif 
silang humoral terhadap antigen-antigen Mtb serta menghasilkan bentuk tidak balas 
Th2 dan gagal menghasilkan sitokin terhadap antigen daripada Mtb. Mencit yang 
diimunisasikan dengan PLMs diadjuvankan dengan AL telah menghasilkan tindak 
balas reaktif silang selular yang signifikan secara in vivo terhadap lisat keseluruhan 
sel daripada Mtb (Mtb-WCL). Pengenalpastian protein-protein daripada PLs dan Mtb 
oleh kumpulan mencit-mencit ini adalah berbeza bergantung kepada jenis adjuvan 
yang digunakan. Secara kesimpulannya, keputusan-keputusan yang diperolehi 
daripada kajian ini menyokong pembangunan keupayaan perlindungan PLs terhadap 
jangkitan Mtb di dalam model haiwan pada masa depan. 
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PROTEOLIPOSOMES FROM Mycobacterium bovis BCG AND Mycobacterium 
smegmatis AS NEW VACCINE CANDIDATES AGAINST TUBERCULOSIS 
 
ABSTRACT 
Tuberculosis (TB) is caused by Mycobacterium tuberculosis (Mtb). It is an infection 
that can be fatal and one of the leading causes of death and illness in the world. The 
bacteria typi cally attack the lungs, but can also attack other parts of the body such 
brain, kidney and spine. Bacille Calmette-Gúerin (BCG) is the world‘s most widely 
used vaccine and is the only vaccine available against TB. Studies show that BCG 
can protect against, or at least ameliorate, severe forms of systemic TB in children, 
particularly meningitis. Nevertheless, it seems to be of low or no protective value 
against pulmonary TB in adults. Thus, candidate vaccines more potent than BCG are 
desperately needed to protect against TB disease and transmission. Considering the 
genomic and antigenic homology between Mtb and non-pathogenic BCG and 
Mycobacterium smegmatis (Ms), we decided to evaluate the potential of 
proteoliposomes (PLs) from BCG and Ms as vaccine candidates against TB. 
Bioinformatics studies predicted the presence of T and B cell epitopes in PLs from 
BCG and Ms which are expressed in vivo by Mtb during infection. Determination of 
human leukocyte antigen (HLA) have shown these epitopes provide the best 
percentage in the population of Malay and Cuba. Therefore, PLs from BCG 
(PLBCG) and Ms (PLMs) were prepared to evaluate the immunogenicity and cross-
reactivity with Mtb antigens. These PLs were confirmed to be spherical and 
homogenous in their size and shape under electron microscopy and chromatographic 
study. We subsequently, evaluated the antigenicity of PLBCG and PLMs in humans. 
We showed that healthy individuals produced IFN-γ in the presence of PLs which 
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could be explained due to BCG vaccination and contact with environmental 
mycobacteria. In contrast, the lower response of IFN- of TB patients could be 
explained by immunodepression and genetic factors/susceptability. In addition, 
ELISA and Western blot analyses showed that the PLs are recognized by sera from 
TB patients, which suggested the presence of Mtb antigens expressed in vivo during 
active infection in PLBCG and PLMs.  Animal studies demonstrated that 
immunization with PLBCG adjuvanted with alum (AL) induced a specific humoral 
immune response with elicitation of a mixed Th1/ Th2 pattern and stimulation of 
specific cellular immune response in vivo with positive delayed type hypersensitivity 
(DTH) response against PLBCG. Immunization with PLBCG combined with 
Montanide ISA 51 VG (MT) elicited a humoral Th2 immune response against 
PLBCG. Mice immunized with PLMs adjuvanted with AL showed a specific 
antibody response against PLMs with elicitation of Th2 pattern. Splenocytes from 
PLMs- immunized mice produced a Th2 pattern of cytokine response in vitro against 
PLMs. Mice immunized with both PLBCG and PLMs adjuvanted with AL and 
PLBCG with MT induced a humoral cross-reactive response against Mtb antigens 
with elicitation of a Th2 pattern but failed to produce cytokine response against Mtb 
antigens. Mice immunized with PLMs adjuvanted with AL produced cellular cross-
reactive responses in vivo with significant increase of DTH response against whole 
cell lysate from Mtb (Mtb-WCL). The pattern of recognition of proteins from PLs 
and Mtb by immunized animals differs depending of the adjuvant used. In 
conclusion, the results obtained in the current study support the future evaluation of 
the protective capability of these formulations in challenge experiments with Mtb in 
animal models.  
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CHAPTER 1 
INTRODUCTION 
1.1  Tuberculosis (TB) 
1.1.1 History of TB 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
(Mtb) that may infect any part of the human body, but most commonly occurs in the 
lungs. It was recognized in ancient and historical times and may have killed 
millions of people compared to other microbial pathogen. The earliest cases of TB 
infection were reported in relics from ancient Egypt, India, and China (Zink et al., 
2007). Additionally, evidence of spinal TB features has been identified in Egyptian 
mummies dating back to 9000 Before Century (B.C) (Hershkovitz et al., 2008). 
Analysis of 483 pre-Columbian skeletons in Chile showed that about 2% of their 
community had TB correlated with bony TB (Arriaza et al., 1995). Subsequently, 
molecular studies have established the presence of Mtb complex DNA in ancient 
bony specimens (Zink et al., 2007; Hershkovitz et al., 2008; Donoghue et al., 2011). 
 
In the Hippocrates era, around 460 B.C, TB was known as phthisis, the most 
widespread disease during that time. Phthisis attacked young adults between the age 
of 18 to 35 and is usually fatal (Frith, 2014). It is believed that phthisis was a 
hereditary disease but not an infectious disease because the infection commonly 
happened across the entire family (Daniel, 2000; Frith, 2014).  
 
In the 18
th
 century TB, known as ‗White plague‘, became an epidemic in Europe and 
resulted in millions of deaths. Then, in the early 19
th
 century, TB is named Scrofula 
and was also known as ―king‘s evil‖ because they believed that the kings of England 
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and France could cure scrofula simply by touching those affected (Wheeler, 2003; 
Frith, 2014). Generally, scrofula is an infection in the lymph nodes, known as 
lymphadenitis and it is the term used for lymphadenopathy of the neck. It can be 
caused by Mtb or atypical mycobacterial (Amir, 2010; Cruz-Knight and Blake-
Gumbs, 2013).  
 
In March 24, 1882, tubercle bacilli, the causative organism for TB, were discovered 
by Robert Koch (Sakula, 1982; Lawn and Zumla, 2011) using methylene blue 
staining (Sakula, 1982). After the discovery, the Sanatorium era begun and in 1982 
the first World TB Day was announced by WHO.  
 
1.1.2 TB incidence 
Globally, TB is the second infectious disease that caused the most death in human 
after Human Immunodeficiency Virus (HIV)/ Acquired immunodeficiency syndrome 
(AIDS). In 2013, approximatey 9 million people were infected with TB. The 
incidence was observed in both developing and industrialized countries. It has 
reported by WHO that an estimated 45% of TB mortality rate and 41% of prevalence 
rate have declined since 1990 to 2013 (WHO, 2014). This means that the world is on 
track in reducing TB incidence and the trend needs to be sustained to achieve the TB-
related United Nations‘ Millenium Development Goals (MDG) to narrow down the 
spread of the TB disease by 2015 (WHO, 2013).  
TB incidence has declined in 6 regions in the world where Europe is the fastest 
region to show the decline at approximately 6.5% per year (Figure 1.1). Eastern 
Mediterranean and South-East Asia showed the slowest decline compared to other 
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regions, at less than 1% and 2% per year respectively (WHO, 2013). In 2012, almost 
8.6 million TB cases were reported worldwide at a rate of 122 cases per 100 000 
population (WHO, 2013) (Figure 1.1). Asia (58%) showed the highest number of TB 
cases compared to other regions, followed by Africa (27%). The highest TB cases in 
Asia were reported in India, followed by China, South Africa, Indonesia and Pakistan 
(Figure 1.2). The other 4 regions showed smaller number of TB cases; 8% in Eastern 
Mediterranean, 4% in Europe and 3% in the Americas. 
 
In 2012, the incidence of TB increased significantly in areas with high rate of HIV 
infection (1.0–1.2 million), particularly in Africa (37%) (WHO, 2013). Additional 
factors also contributed to the high TB burden including Multi-drug resistant-
Tuberculosis (MDR-TB), Extensively Drug-Resistant Tuberculosis (XDR-TB), 
homelessness and poverty, increasing number of refugees, reduction of governmental 
support in TB prevention and lack of treatment programs (WHO, 2013). Another 
reason for the rising rate of TB cases is due to the high rate of immigration from 
countries with a high TB incidence (Abubakar et al., 2011; Pareek et al., 2011).  
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Figure 1.1: TB incidence rates in 2012. (WHO Global Tuberculosis Report, 2013)  
 
 
Figure 1.2: TB incidence in top-ten countries, 2012 (WHO Global Tuberculosis 
Report, 2013) 
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1.1.3 Mycobacterium tuberculosis  
Mycobacterium tuberculosis (Mtb) is a species from the Mycobacteriaceae family 
and belongs to a distinctive genus of Mycobacterium (Figure 1.3). It is a pathogenic 
bacterium and the causative agent for TB which was discovered by Robert Koch in 
1882. It has a complex cell wall structure which hyropobic and waxy; composed of 
proteins intermingled in a matrix of peptidoglycan, rich mycolic acid, lipids and 
carbohydrates (Brennan et al., 2003) (Figure 1.4). They are Gram-positive aerobic 
bacteria, non-motile, non-spore forming, straight or slightly curved rod-shaped 
microbes, 1-4 m in length and between 0.3-0.6 m in diameter (Iseman, 2000; 
Lawn and Zumla, 2011). Mtb contains granules and vacuoles and grows very slowly 
with a doubling time of 18-24 hours. 
 
The genome of Mtb is 4,411,529 base pairs (bp) with 3924 predicted protein-coding 
sequences. The Mtb genome was sequenced and published in 1998 (Cole et al., 
1998; Ismael et al., 2004). Mtb has a high content of guanine (G) and cytosine (C) in 
its DNA (65.6 %). The high GC content may be one of the survival strategies 
employed by the bacterium, since stability of DNA increases directly with number of 
GC bonds (Cole et al., 1998).  
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Figure 1.3: Scanning electron microscope of Mtb (under 15549x magnification) 
(Centers for Disease Dontrol and Prevention, CDC).   
 
 
Figure 1.4: Schematic representation of the mycobacterial cell wall (Gokhale et al., 
2007). 
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1.1.4 Transmission and pathogenesis 
Airborne transmission is the most frequent route of Mtb infection (Figure 1.5). 
Although, it can be transmited through the gut, genitourinary tract and eye, or via 
compromised skin. Mtb is expelled through the airway by a person who have 
pulmonary or laryngeal TB and is carried in droplets in the air (McNerney et al., 
2012), called droplet nuclei (1-5 m in diameter) which are very light and can 
remain in air for several hours depending on the environment (McNerney et al., 
2012). These bacteria traverse the mouth or nasal passages, upper respiratory tract 
and bronchi to reach the alveoli of the lungs. Once the smaller droplet nuclei reach 
the alveoli, the organisms are taken up by alveolar macrophages; some of them are 
killed and a few multiply in the alveoli, which then enter the bloodstream and spread 
throughout the body (Russell et al., 2010; Orme, 2014) (Figure 1.5). Mtb will reach 
any part of the body and rapidly develop into either active disease or remain dormant 
without causing any symptoms (Schluger and Rom, 1998; Frieden and Driver, 2003). 
Infection does not necessarily lead to TB disease; in fact, it was reported in several 
studies, that only 3–10% of immunocompetent individuals that are infected will 
develop the disease during their life-time (Lawn and Zumla, 2011; Zumla, 2011), 
while more than 90% of infected subjects sustain infection in a subclinical stage 
known as latent TB infection (LTBI), in which the pathogen remains in a quiesce  nt 
state (McNerney et al., 2012). LTBI may turn to TB disease by a re-activation 
process (Figure 1.6). A person with LTBI has a 5-10% chance of developing active 
TB in their lifetime during the first 5 years after becoming infected (Harries, and 
Dye,2006; WHO, 2015). Re-activation starts when the immune system becomes 
weakened and the dormant pathogen become active to cause TB disease. 
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Figure 1.5: Summary of TB transmission and pathogenesis (Nunes-Alves et al., 
2014) 
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Figure 1.6: The choronolgy of Mtb infection (Young et al., 2008). 
 
1.1.5 Symptoms of TB 
People with LTBI do not have symptoms because they are in inactive state of the 
disease. People with TB disease may have any or all of the following symptoms; 
cough, fatigue, loss of appetite, weight loss, fever and night sweats. As the disease 
progresses, infected individuals may cough up blood (hemoptysis) and develop 
severe breathing problems. The symptoms of extra-pulmonary TB vary widely 
depending on which area of the body is infected. Thus, if TB affects the lymph 
nodes, it can cause swollen glands and a painless red mass, usually at the sides and 
base of the neck. When bone is infected, the spine is typically involved which causes 
back pain lasting weeks to months. Sometimes, the disease can progress to the spinal 
cord, causing paralysis. Mtb can also infect the joints, with slow progressive swelling 
and pain, usually in a large joint such as the knee. 
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1.1.6 TB in children 
In 2012, approximately 0.5 million TB cases occurred in children from the 8.6 
million TB incidence worldwide. From an estimated 6% of global TB incidence (530 
000) in 2012, 8% (74 000) of the incidence caused death among HIV-negative 
children (WHO, 2013). WHO estimated that TB incidence among children occurs in 
those younger than 15 years old. Childhood TB appears to be increasing in many 
parts of the world (Nelson and Wells, 2004b). In many industrialized countries, this 
situation is associated with new immigration patterns (Nelson and Wells, 2004a; 
Nelson et al., 2004; Marais, 2014). This trend is associated with many factors 
including poor economic situation and poor public health infrastructure, rising rates 
of HIV infection, difficulty of diagnosing childhood TB and the difficulty of 
diagnosing HIV-associated pulmonary infections in children (Raviglione et al., 2012; 
WHO, 2013).  
 
An estimated 90% of cases in children progressed to serious TB due to primary 
infection before the age of 2 within the first 12 months without significant 
symptoms. Primary infection between the age 2 and 10 rarely progressed to serious 
TB, and disease progression is associated with significant clinical symptoms. 
Children older than 3 years who show TB symptoms should be clinically diagnosed 
before serious disease progression. Frequently, children with primary infection after 
10 years of age are more likely to progress to adult-type disease (Centers for Disease 
Control and Prevention). However, early effective intervention in this group will 
reduce the burden of caveating disease and associated disease transmission in the 
community.  
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1.1.7 TB in Malaysia  
TB is the most common infectious disease with the highest number of deaths and 
remains as a major health problem in Malaysia. Moreover, it is the second biggest 
killer worldwide after Acquired immunodeficiency syndrome (AIDS) (WHO, 2013). 
As a middle-income country, the number of estimated TB cases continues to rise 
with rates of TB incidence and mortality of 82 and 8.5 cases per 100 000 population, 
respectively. In Malaysia, the number of TB cases detected annually is relatively 
higher than the reported incidence of HIV. About 9% of TB cases are being 
diagnosed among people living with HIV/AIDS (WHO, 2011). 
 
The Ministry of Health reported an average of 18 500 TB cases between 2007 and 
2010 while in 2011, 20 666 new TB cases were registered (MOH, 2011). Pulmonary 
TB is the most common infectious disease in Malaysia. However, extra pulmonary 
TB showed an increase and has spread to the entire community every year. In 2011, 
2.7% of TB cases involved children of ≤14 years old, while 12.3% involved those of 
≥65 years old. The majority (69.5%) of TB patients are between 21-60 years age.  
 
Among the 15 states, Sabah recorded 143.7 cases/ 100 000 population which is the 
highest in the country, followed by Wilayah Persekutuan (121.7 cases/ 100 000 
population), Sarawak (87.4 cases/ 100 000 population), Pulau Pinang (68.7 cases/ 
100 000 population) and Kelantan (55.5 cases/ 100 000 population) (MOH, 2011). 
Approximately 13.9% of TB cases in Malaysia were discovered among the 
immigrant population (MOH, 2011).   
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TB incidence has not significantly reduced because of the complexities surrounding 
the diagnosis, management, and treatment of TB, co-infection with communicable 
disease such as HIV/AIDS and non-communicable diseases (NCDs) (e.g. diabetes 
mellitus), challenges related to the treatment of drug-resistant Mtb strains, poverty, 
illiteracy and smoking (MOH, 2012). In Malaysia, the incidence of TB-HIV in 1990 
was six cases and it reached to 933 cases in the year 2002 (MOH, 2012). 
Additionally, it was reported that diabetes mellitus is the leading risk factor for TB in 
Malaysia. Diabetic patients are three times more likely to develop TB (Dooley and 
Chaisson, 2009). 
 
1.1.8 Risk factors 
1.1.8(a) Human Immunodeficiency Virus (HIV) 
WHO has declared that TB is the number two killer after HIV/AIDS. One in ten 
people infected with TB (but who are not infected with HIV) becomes ill or at least 
infected with TB once during his lifetime. Immunocompromised individuals such as 
HIV patients are at greater risk of developing active TB disease, 12 ‒ 20 times higher 
than normal individuals. In 2012, 8.6 million people were infected with TB while 1.3 
million people died from TB: there were 320 000 deaths in HIV-infected people and 
estimated 170 000 deaths were from MDR-TB (WHO, 2013). Three-quarters of total 
TB deaths occurred in Africa and Southeast Asia regions, in which South Africa and 
India accounted for one third of the global TB deaths (Lawn and Zumla, 2011; 
Zumla, 2013).  
 
 13 
 
1.1.8(b) Non-communicable diseases (NCDs) 
While TB has dominated the number of death worldwide, NCDs including diabetes 
mellitus, diseases related to smoking and alcoholism, chronic respiratory and 
cardiovascular diseases, and also mental disorders grew concomitantly as associated 
diseases with increased number of TB case (Marais et al., 2013; Lönnroth et al., 
2010a).  
 
NCDs are one of the risk factors for TB, mainly for the development of the disease as 
early as infection due to the the negative impact of NCDs on the host defense 
(Sopori, 2002; Wang et al., 2002; Cegielski and McMurray, 2004). Additionally, 
NCDs may make difficulties in management and treatment of TB, due to clinical 
challenges among people with diabetes mellitus and behavioral challenges among 
those who suffer from alcohol use disorders (Rehm et al., 2009; WHO, 2009). 
Moreover, TB can trigger or aggravate NCDs. For example, TB can worsen glucose 
control and lead to diabetes mellitus among those at high risk groups (WHO, 2009). 
TB, although not a classical risk factor for chronic respiratory disease, is one of the 
main causes of lung sequelae and bronchiectasis. TB also identified as an 
independent risk factor for chronic respiratory disease in a recent review (Salvi and 
Barnes, 2009).  
 
Lönnroth et al. (2008) concluded that heavy drinkers consuming ~0.40 g alcohol a 
day and/or person who have a bad habit of alcohol use have three times risk for 
getting TB. A person with low to moderate drinking of alcohol has a lower risk to 
develop TB (Lönnroth et al. (2008). This association seems to be a causal factor for 
TB progression (Rehm et al., 2009). Additionally, alcohol has been showed a direct 
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toxic response on the immune system. Several studies recommend that excessive 
alcohol consumption can weaken cell-mediated immunity and macrophage functions, 
which is important for the host response to Mtb infection (Szabo, 1997; Cegielski 
and McMurray, 2004; Rehm et al., 2009). Moreover, previous studies have 
demonstrated that heavy alcohol consumption may be one of cause of the 
malnutrition deficiencies, which can also weaken immunity (Gonzalez-Reimers et 
al., 2008; Knudsen et al., 2014), which can also weaken immunity (Porretta et al., 
2012).  
 
Globally, severe malnutrition in parts of the developing world causes a large increase 
in the risk of developing active TB (Cegielski and McMurray, 2004; Lönnroth et al., 
2010b; Dye et al., 2011; Cegielski et al., 2012), due to its damaging effect on the 
immune system. Along with overcrowding, poor nutrition may also contribute to the 
strong link observed between TB and poverty. 
 
1.1.9 Immune response against Mtb 
1.1.9(a) Innate immune response 
Host immune response plays an important role in the defense against Mtb during 
primary infection (Cooper et al., 2011). The component of the innate immune system 
comprised the anatomical barriers, as well as the complement system and several 
types of innate immune cells, including various leukocytes: macrophage, dendritic 
cells (DCs), granulocytes and natural killer (NK) cells (Janeway et al., 2001; Quintin 
et al., 2014). 
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Infection of Mtb begins with the inhalation of small droplet nuclei containing Mtb 
into the pulmonary alveoli. When Mtb enters the alveolar macrophage, Mtb are 
phagocytised by DCs, alveolar type II pneumocytes and monocyte-derived 
macrophage (Van Crevel et al., 2002; Hossain and Norazmi, 2013; Quintin et al., 
2014).  
 
Another crucial step in an effective host innate response is the recognition of Mtb or 
mycobacterial products on macrophages and DCs by toll-like receptor (TLR) (Belvin 
and Anderson, 1996; Medzhitov et al., 1997; Visintin et al., 2001). In mammals, 
TLR is an important connection between the innate and adaptive immune systems, 
and act as linkers for the recruitment and activation of the adaptive immune system 
(Werling et al., 2003; Akira et al., 2004; Pasare et al., 2005; Kanczkowskial et al., 
2007) in host defence against microbial pathogens, particularly Mtb (Kulchavenya, 
2013). There are four TLRs involved in recognition of Mtb namely, TLR2, TLR4, 
TLR9 and possibly TLR8 (Tapping and Tobias, 2003; Bulut et al., 2005; Davila et 
al., 2008). 
 
The mycobacterial glycolipids, including lipoarabinomannan (LM) and 
phosphatidylinositol-mannosides (PIM), are the main factors that activate TLR2 
(Ferwerda et al., 2005). Several mycobacterial antigens, such as the 19-kilo Dalton 
(kDa) lipoprotein, activate the innate immune response through TLR2 (Brightbill et 
al., 1999). In addition, several antigens such Hsp 60, 65, 70 and 38 kDa glycoprotein 
are reported to activate TLR4 (Jung et al., 2006; Jo et al., 2007; Kleinnijenhuis et al., 
2011). A study by Bhatt and Salgame (2007) demonstrated that TLR2 is a central 
protein for in vitro activation of the innate immune response. In addition, TLR2 was 
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shown to influence the maintenance of Th17 cells in the lung of Mtb-infected 
animals (Teixeira-Coelho et al., 2011) and granuloma formation (Drennan et al., 
2004; Teixeira-Coelho et al., 2011), but not bacterial burden (Sugawara et al., 2003; 
Drennan et al., 2004; Bafica et al., 2005; Teixeira-Coelho et al., 2011). In addition, 
another important TLR member, TLR8 was suggested to have a potential role in TB-
susceptibility in male TB patients and in macrophage immune responses to BCG 
infection (Davila et al., 2008). 
 
Host recognition of Mtb or mycobacterial products will lead to immune cell 
activation and production of specific cytokines. IFN- is the central cytokine and 
plays a key role in the Th1 development leading to host defence against Mtb 
infection (Belosevic et al., 1989; Sher and Coffman, 1992; Gately et al., 1998). The 
importance of IFN-was demonstrated by the increased susceptibility to 
mycobacterial infection of children with IFN-receptor (IFN-R) deficiency 
(Jouanguy et al., 1996; Jouanguy et al., 1997) and in IFN-R knockout mice (Cooper 
et al., 1993; Flynn et al., 1993). In humans, IFN-alone is insufficient to enhance 
the ability of macrophages to control Mtb infection. Thus, other cytokines such as 
Tumor Necrosis Factor (TNF)- and Interleukins (IL) are synergistically important 
in controlling the infection. 
 
TNF- is produced by T cells, macrophages and DCs (Valone et al., 1988; Barnes et 
al., 1993; Henderson et al., 1997; Ladel et al., 1997; Serbina and Flynn, 1999) and 
plays a key role in granuloma formation. In TB patients, TNF- is detected at the site 
of infection (Barnes et al., 1993; Law et al., 1996; Casarini et al., 1999). IL-1β is 
also detected at the site of infection (Schauf et al., 1993; Law et al., 1996; Bergeron 
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et al., 1997). Studies in mice suggested that IL-1β plays an important role in TB 
eradication (Juffermans et al., 2000; Yamada et al., 2000). In addition, IL-12 is also 
one of the crucial cytokines in controlling Mtb infection and is secreted following 
phagocytosis of Mtb by macrophages (Henderson et al., 1997; Ladel et al., 1997).  
The administration of IL-12 DNA can reduce the bacterial numbers in mice with 
chronic Mtb infection (Lowrie et al., 1999). Furthermore, IL-12, IL-18 and IL-15 are 
also important in controlling Mtb infection by increasing the production of IFN- 
(Berg et al., 2002; Berg et al., 2003). 
 
1.1.9(b) Adaptive immunity  
1.1.9(bi) Antibody responses against Mtb 
Humoral immune response is mediated by antibodies that are produced by activated 
B lymphocytes (plasma cells) and provides the most effective response against 
extracellular pathogens. These antibodies bind specifically to the antigens and are 
important elements in protection against infectious diseases (Janeway, 2005). The 
immune system then neutralizes or eliminates the pathogen from the body through 
ingestion and degradation of the antibody-antigen complex by phagocytes or by cell 
lysis (Abbas and Lichtman, 2001).  
 
 
Recent studies showed that Mtb induced a humoral immune response to various 
mycobacterial antigens in humans despite being an intracellular pathogen (Steingart 
et al., 2009). Intradermal BCG vaccination elicits two classes of antibodies such as 
IgG and IgM. These antibodies are directed to several mycobacterial antigens such 
glycolipid lipoarabinomannan (LAM) which is known as the major cell wall antigen 
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(Brown et al., 2003; de Valliere et al., 2005). Moreover, a study by de Valliere et al. 
(2005) revealed that antibody response shows to boost innate and cell mediated 
immune responses against mycobacteria.  
 
The humoral immune response against mycobacterial antigens vary depending on the 
phase of infection (Kunnath-Velayudhan and Gennaro, 2011). For example, in the 
case of persons with LTBI, they do not have active TB and produce antibody to a 
different repertoire of Mtb antigens compared to those with active TB. Moreover, 
animal and human studies have demonstrated that increased antibody titres was 
directly correlated with the level of mycobacterial burden (Achkar et al., 2010; 
Kunnath-Velayudhan et al., 2010; Yu et al., 2012). The observation of high antibody 
titer in active TB patients against mycobacterial antigens has supported the 
disagreement that these antibodies are not protective. However, similar argument 
was not used to challenge the perception that immunity against TB is typically based 
on cell and cytokine mediated, since most of TB patients despite having normal T 
cell function and producing high IFN- (Okamoto et al., 2005; Cavalcanti et al., 
2012). Interestingly, antibody titers can be used as markers for TB, in the same way 
that increases of IFN- levels indicate the progression of TB (Lin et al., 2009; Diel et 
al., 2011). Although not all the  antibodies induced by Mtb infection are protective, 
several reports highlight the potential importance of specific antibodies in the 
defense against Mtb (Glatman-Freedman et al., 2000; Ciurana et al., 2004; Lopez et 
al., 2009; Olivarez et al., 2009; Acosta et al., 2010; Acosta et al., 2012; Achkar and 
Casadevall, 2013; Acosta et al., 2013; Alvarez et al., 2013 ).  
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1.1.9(bii) Cellular responses against Mtb 
Cell-mediated immune response is important to control Mtb infection. This response 
provides a major protective immunity to Mtb rather than the humoral responses 
(Kaufmann, 1995; Feng et al., 1999). Cluster of differentiation (CD) 4+ T cells are 
central to the human immune response to Mtb infection (Boom, 1996), and supported 
by other T cell subsets such as CD8+ cytolytic T cells (CTL) and unconventional T 
cells and CD1+ T cells) (Kaufmann, 2000; Flynn and Chan, 2001; Kaufmann, 
2001; Jung et al., 2005; Kaufmann, 2013).  
 
CD4+ T cells recognize antigens via major histocompatibility complex (MHC) class 
II molecules (Dorhoi et al., 2012), whereas, CD8+ T cells also contribute to immune 
protection against TB (Cooper, 2009) by recognition of antigens presented by MHC 
class I molecules (Dorhoi et al., 2012). In general, CD4+
 
is responsible for directing 
an immune response by activating effector cells, whereas CD8+ T cells
 
is the killer 
cells that lyse infected cells by producing various cytokines such as IFN and TNF-
α (Schluger and Rom, 1998). Some authors have reported that T cells such as CD4+, 
CD8+ and  T cells are important in controlling TB infection in mice and cows 
(Cassidy et al., 2001; Walravens et al., 2002; Vesosky et al., 2004).  
 
Activated CD4+ T cells can differentiate into either Th1 cells which secrete specific 
cytokines IFN and TNF-α, or into Th2 cells secrete IL-4, IL-5, IL-10 and IL-13. 
The activation of Th1 cells by Mtb antigens resulted in cytokine production, mainly 
IL-2 and IFN(Huygen, 2014; Montagnani et al., 2014These cytokines will 
activate macrophages and other T cells (CD8+ and  T-cell) to provide strong 
protection against bacterial infection (Grange et al., 1995; Feng et al., 1999; Flynn 
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and Chan, 2001; Raupach and Kaufmann, 2001). Th2 cells play important role in 
immune responses during Mtb infection by counter-regulating Th1 cells and 
impairing protective immunity against TB (Romagnani, 2005; Keir et al., 2008; De 
Libero and Mori, 2005). Th2 cells also contribute to down modulation of the immune 
response to the pathogen (Kaufmann, 2013) and to TB reactivation (De Libero and 
Mori, 2005; Keir et al., 2008; Gold et al., 2010; Kaufmann, 2013). 
 
There are two major lysis mechanisms of CD8+ T cells in protecting against Mtb. 
Firstly, CD8+
 
T cells expressed perforin and granzymes to lyse the infected cells. In 
humans, CD8+
 
T cells produce granulysin that is toxic to Mtb which lyse the infected 
cells (Stenger et al., 1997; Stenger et al., 1998). Secondly, CD8+ T cells lyses the 
target cells via the Fas/FasL pathway (Clark et al., 1995). In addition to killing of 
infected cells, CD8+ T cells mediate anti-microbial effector function by secreting 
related cytokines such IFN and TNF-α (Herbein, 1997). he T cells and CD1+ 
restricted T cells also produce IFNwhich activate anti-mycobacterial activities in 
macrophages and inhibit the mycobacterial growth (Raupach and Kaufmann, 2001) 
which is supported by TNF-α. Tsukaguchi et al. (1995) demonstrated that  T cells 
have the capacity to display cytotoxicity and produce IFN-in response to Mtb 
infected macrophages. A study performed by D‘Souza et al. (1997) reported that  
T cells contribute in early stages of TB infection. As the disease progress, apoptosis 
mediated by Fas/FasL clears the majority of Mtb and causes reactivation of  T cells 
(Li et al., 1998). Raja (2004) suggested that T cells are important in patients with 
LTBI (Flynn and Chan. 2001; North and Jung, 2004). Studies performed in a primate 
model demonstrated that the number and activity of T cells increased during 
primary mycobacterial infection and after BCG vaccination (Barnes et al., 1992).  
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The CD1 family (group I CD1 molecules: CD1a, CD1b, CD1c and group II CD1 
molecule; CD1d) is the least common T cell subset in human peripheral blood and 
the lungs. CD1 plays a significant role in protection against microbial pathogens like 
Mtb that contain unique lipids on their cell walls or membranes (Brigl et al., 2004; 
Cohen, et al., 2009). In humans, CD1a, b, and c have been associated with effective 
immune response to leprosy and mycobacterial infections. Brigl et al. (2004) have 
shown that CD1 expressions are down-regulated following exposure to live Mtb. 
 
1.1.10 Control of TB 
1.1.10(a) Diagnosis  
The standard TB diagnosis in clinical examination is routinely performed by acid fast 
bacillus, followed by culture on solid or liquid media for confirmation (Aber et al., 
1980) as recommended by WHO guidelines (WHO, 2010). The result of Mtb culture 
can be obtained up to 8 weeks and in 10‒20 % of cases the bacillus is not 
successfully cultured (Pottumarthy et al., 1999). If the patient has pulmonary TB by 
radiographs but no diagnostic sputum sample, then bronchoscopy should be 
considered to confirm the diagnosis. Rapid and sensitive tools for diagnosis are 
required due to the increased incidence of TB worldwide particularly in the HIV 
endemic regions and the length of time required for the classical tests. Currently, 
rapid molecular tests are being used for the detection of pulmonary TB (Vassall et 
al., 2011; Boyle et al., 2014).  
 
There are several new techniques being developed including fluorescent microscopy 
which used similar principle as conventional light microscopy. This technique 
 22 
 
required an ultraviolet light source such as a high-pressure mercury vapour lamp and 
an acid-fast fluorochrome dye for staining (Steingart et al., 2006). The bacilli are 
then visibly seen as fluorescent green rods. On the other hand, the most rapid liquid 
culture system used in laboratory is BACTEC 460. The use of BACTEC for culture 
can decrease the detection time when culturing using solid media (1‒2 months to 1‒2 
weeks) (Enarson and Ait-Khaled, 2003). Safety issues concerning the radioactivity of 
BACTEC and its cost, however, prevents its widespread application. 
 
The most recent and advanced technologies to diagnose TB are Nucleic acid 
amplification tests (NAATs) and Interferon-gamma (IFN-) assay (IGRAs). NAATs 
are used following microscopy to distinguish Mtb from other smear-positive 
mycobacteria. The technology is able to detect small amounts of genetic material 
(DNA or RNA target sequences) from Mtb due to repetitive amplification of the 
target sequences (Dinnes et al., 2007). If no target organism is present, there will be 
no amplification. The most common technique used is polymerase chain reaction 
(PCR) (Ramachandran and Paramasivan, 2003) and a new technique recently 
developed is Xpert MTB/RIF. On the other hand, IGRAs has been developed to 
replace the tuberculin skin test (TST) for TB detection of either active TB or latent 
TB. The assay is based on purified protein derivative (PPD) and region of difference 
(RD)-1 specific antigens are able to discriminate between Mtb and Mycobacterium 
avium intracellular complex infection (Streeton et al., 1998). Two types of valuable 
commercial IGRAs: Quantiferon-TB Gold and the newer version of Quantiferon-TB 
Gold In Tube (QFT-GIT), based on ELISA measure the amount of IFN-produced 
in response to specific Mtb antigens [QFT-G: Early secreted Antigenic Target 
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(ESAT)-6 and CFP-10, QFT-GIT: ESAT-6, CFP-10 TB7.7]; and enzyme-linked 
immunospot - based T-SPOT.  
 
The assays measure the number of peripheral mononuclear cells that produce IFN-
after stimulation with ESAT-6 and CFP-10. The antigens in IGRAs are absent in 
most of non-tuberculous mycobacteria (NTM) and BCG strain (Anderson et al., 
2000; Mahairas et al., 1996; Harboe et al., 1996). Although, IGRAs cannot 
distinguish between active TB and LTBI (Herrera et al., 2010), IGRAs results are not 
confounded by BCG vaccination and less likely to be confounded by exposure to 
NTM (Lange et al., 2009). Thus, IGRAs shows advantages over the TST in 
identifying human immune response to Mtb, particularly in population with high 
NTM exposure and general vaccination.  
 
1.1.10(b) Treatment 
TB can be treated by chemotherapy and this approach started in the late 1940s with 
the introduction of streptomycin. The objective of this approach is to eradicate all 
tubercle bacteria from the patient and to prevent secondary resistant bacteria. 
Subsequently, several drugs were  introduced including p-aminosalicylic acid (PAS) 
(1946), isoniazid (INH) (1952), cycloserine (1955), kanamycin (1957), rifampin 
(RIF) (1965), ethionamide (1966), ethambuthol (ETH) (1968) and pyrazinamide 
(PZA) (1970) (Friedman, 2000). The usual standard drug regiment short course 
chemotherapy consists of 2 months of INH, RIF, PZA and ETH, 4 months of INH 
and RIF. The drugs must be taken either daily or 3 times per week and they have to 
be given under direct observation (DOTs) by health-care staff as recommended by 
WHO (WHO, 2010).  
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Regular drug treatment is a pre-requisite for treatment success. However, under 
certain circumstances, the doctor may have modified the particular needs of 
individual patients. The great majority of patients can be considered as non-
infectious after 2 weeks of effective drug treatment. If the treatment is taken 
irregularly, there may be serious consequences: the Mtb may become resistant to the 
drugs which can cause MDR-TB, where TB cannot be cured or TB disease can 
spread to others leading to death. 
 
ETH is added if MDR-TB is suspected (American Thoracic Society, 1993). ETH 
inhibits the synthesis of arabinogalactan and interrupts the mycobacterial cell wall 
synthesis (Mikusova et al., 1995). INH is important in inhibiting the synthesis of 
mycolic acid (Petrini and Hoffner, 1999). PZA plays an important role in the 
intensive phase of the bacteria. PZA produced specific enzyme to inhibit the fatty 
acid synthesis and affects the mycobacterial energy production for survival 
(Mitchinson et al, 2005). RIF is an important agent in the treatment of TB and has 
bactericidal properties against both intracellular and extracellular Mtb (Friedman et 
al., 2000). In the late 1970s, TB drug development stopped as it was assumed that the 
effective drug and the combination with BCG vaccination programs would lead to 
the prevention of TB as a public health threat. Unfortunately, not all TB patients 
received an effective control of TB treatment in certain areas (Gandhi et al., 2006; 
Tadesse et al., 2011). Nachega and Chaisson (2003) reported that this phenomenon 
resulted in the MDR-TB defined as Mtb that is resistant to at least two drugs, INH 
and RIF. Therefore, an effective surveillance is very important in reducing the 
potential for MDR-TB, and this is one of the essential factors in gaining control of 
the global TB problem.  
